Heron Therapeutics (HRTX) Asset Utilization Ratio (2011 - 2026)

Heron Therapeutics (HRTX) has reported Asset Utilization Ratio for 12 consecutive years, with 0.61 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Asset Utilization Ratio fell 5.22% year-over-year to 0.61; the trailing twelve-month figure through Jun 2026 stood at 0.61 (down 5.22% YoY), and the FY2025 full-year result was 0.63, changed 0.03% from the prior year.
• Asset Utilization Ratio grew to 0.61 in Q2 2026 per HRTX's latest filing, from 0.6 in the prior quarter.
• Across five years, Asset Utilization Ratio topped out at 0.64 in Q3 2025 and bottomed at 0.31 in Q1 2022.
• Historically, Asset Utilization Ratio has averaged 0.55 across 5 years, with a median of 0.6 in 2024.
• The sharpest annual moves came in 2022 and 2026: Asset Utilization Ratio jumped 67.06% in 2022, then fell 5.23% in 2026.
• Over 5 years, Asset Utilization Ratio stood at 0.41 in 2022, then soared by 36.59% to 0.56 in 2023, then increased by 13.02% to 0.64 in 2024, then decreased by 3.47% to 0.61 in 2025, then decreased by 1.16% to 0.61 in 2026.
• According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.61, 0.6, and 0.61 for Q2 2026, Q1 2026, and Q4 2025 respectively.